Actively Recruiting
Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya
Led by Kenyatta National Hospital · Updated on 2026-01-12
1980
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
K
Kenyatta National Hospital
Lead Sponsor
E
Emory University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to evaluate a multi-component care strategy called DADA LINK to improve cervical cancer screening and treatment connection among women aged 25 to 49 years in Kenya. The highest rates of cervical cancer occur in sub-Saharan Africa, with it being the leading cause of cancer death among Kenyan women. This study focuses on overcoming barriers at the patient, provider, and facility levels by using tailored strategies based on earlier research and clinic assessments in Nairobi County. The trial compares clinics using the DADA LINK integrated care package, which includes HPV self-sampling kits, care navigation by trained non-physician staff, and use of a mobile health platform called WEMA, against clinics continuing usual care practices. Care coordinators at intervention clinics motivate staff to follow cervical cancer care guidelines, collect patient exit survey data, and manage screening and treatment tracking through the WEMA app. The study lasts 12 months, with an additional 6-month follow-up to assess costs and maintenance of the care strategies. Participants' cervical cancer screening and treatment data will be collected from clinic records by study staff. Researchers will measure how many women complete screening during clinic visits and how many receive follow-up triage or treatment within 12 months. The WEMA system also supports communication with patients via text messages to improve attendance. This comprehensive monitoring aims to assess both the implementation and effectiveness of the care package over the study period.
CONDITIONS
Brief Title
Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women ages 25 to 49 years
You will not qualify if you...
- Pregnant women
- Women 6 weeks postpartum or less
- Women already confirmed to have cervical cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive HPV self-sampling kits and support from care navigators using an mHealth platform to facilitate cervical cancer screening and linkage to treatment.
Visits as needed for screening and follow-up
Duration - Up to 12 months
Participants receive follow-up communication via mHealth messages regarding HPV test results and support for triage and treatment within 12 months.
Follow-up via text messages and clinic visits as needed
Trial Site Locations
Total: 1 location
1
Kenyatta National Hospital
Nairobi, Kenya
Actively Recruiting
Research Team
A
Agnes K Karume, MBChB, MBA, MPH
M
Millicent Masinde, MBChB, MMed, Fell.Gyn Oncology
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here